While GLP‑1s have dominated budget conversations and boardroom anxiety, cancer costs are accelerating quietly—and far faster. Cancer has always been expensive, but now it’s one of the most volatile, complex and quickly accelerating areas of employer risk.
Yet many employers simply assume their cancer benefits are “covered.” They offer something—a navigation app, a second‑opinion hotline, a point solution—and believe they’ve built a strategy.
But offering “something” is not a strategy. And it certainly is not evidence-based care.
